Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL3 | Q96JM7 | 5/20 | 0.45 |
| ▸ | TRPV4 | Q9HBA0 | 8/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.43 |
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | ACACA | Q13085 | 1/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | TACR3 | P29371 | 1/20 | 0.42 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1422418 | 0.92 | IRAK4 (0.43) | L3MBTL3TRPV4IRAK4L3MBTL1ACACB | |
| SCHEMBL1422325 | 0.90 | L3MBTL3 (0.49) | L3MBTL3TRPV4IRAK4L3MBTL1ACACB | |
| SCHEMBL1422216 | 0.90 | ACACB (0.43) | L3MBTL3TRPV4IRAK4L3MBTL1ACACB | |
| SCHEMBL1422177 | 0.90 | IRAK4 (0.44) | L3MBTL3TRPV4IRAK4L3MBTL1ACACB | |
| SCHEMBL1421156 | 0.90 | IRAK4 (0.45) | L3MBTL3TRPV4IRAK4L3MBTL1ACACB | |
| SCHEMBL1420845 | 0.89 | IRAK4 (0.44) | L3MBTL3TRPV4IRAK4L3MBTL1ACACB | |
| SCHEMBL1421257 | 0.89 | IRAK4 (0.44) | L3MBTL3TRPV4IRAK4L3MBTL1ACACB | |
| SCHEMBL1420712 | 0.89 | IRAK4 (0.44) | L3MBTL3TRPV4IRAK4L3MBTL1ACACB | |
| SCHEMBL1422412 | 0.89 | IRAK4 (0.47) | L3MBTL3TRPV4IRAK4L3MBTL1ACACB | |
| SCHEMBL1421088 | 0.88 | IRAK4 (0.45) | L3MBTL3TRPV4IRAK4L3MBTL1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8227613-B2 | Heteroaryl carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227613-B2 | Heteroaryl carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| US-8227613-B2 | Heteroaryl carboxamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2012-07-24 | — | — | US | disclosed |
| EP-2297137-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2011-03-23 | — | — | EP | disclosed |
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | HOFFMANN-LA ROCHE, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2009153182-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
| WO-2009153182-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318467-A1 | NOVEL HETEROARYL CARBOXAMIDE DERIVATIVES | CCR3, CCR2, CCR1 | L3MBTL3 2613/4885TRPV4 181/4885IRAK4 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.